Without too many surprises, the SMI, a flagship index of six Swiss Exchange, started the day in the red. The Zurich Stock Exchange fell by around 1.7% to the opening. At the end of the morning, however, she bounced at -0.5%.
The pharmaceutical industry, in the viewfinder of Donald Trump who intends to obtain price reductions on the American market, also followed this downward trend at the start of the day. The title of Novartis displays a drop of approximately 1%, while the one rock is falling by just over 2%and the action of Lonza is set back by 1.7%, finally the price of Alcon loose 1.1%.
The American president announced on Thursday that he was planning to obtain large companies in the sector, Swiss or not, a drop in prices by the end of September. Swiss pharmaceutical companies remain, for the moment, spared by customs duties but the prospect of specific taxes on the sector remains current. In mid-April, the United States trade department has launched an investigation to determine to what extent imports of drugs, their ingredients and their derivative products threatened the security of the country. A device already used to justify customs barriers on steel.
Analysts of the ODDO BHF bank estimate that customs taxes of around 10 to 15% on Swiss pharmaceutical products could cost up to $ 800 million (647 million francs) per year in Novartis and a billion (808 million francs) for Roche. For Novartis, around 42% of the turnover expected for 2025, comes from the American market.
At the opening, Logitech accuses the most severe decline. The title of the specialist in computer devices is behind 3.5%.
Development follows.
